Learn more about the geneType™ prostate cancer test which goes beyond hereditary risk, looking at genetic and clinical risk factors to give you a comprehensive risk prediction so that you can take preventative steps to improve health and mitigate your risk.
Risk stratification can enable more informed decision-making discussion about individualised screening strategies.
Whether you are discussing the impact of lifestyle habits on risk of developing prostate cancer, or you are strategising about PSA screening intervals or liquid biopsy options, geneType™ opens the door to risk-reduction conversations with your patient.
geneType™ reports are structured to make the results easy to interpret and communicate to a patient.
The geneType™ for Pancreatic Cancer report includes:
geneType™ for Pancreatic Cancer is appropriate for:
Register as a provider; our team will provide clinical education and other resources as needed.
We will send kits to your clinic to have on hand.
Discuss geneType™ with your patient.
Would geneType™ help them qualify for additional risk reduction strategies?
Complete the Test Requisition form, collect a saliva sample from the patient with the collection kit provided and return both to Rhythm.
You will have the option to use a paper requisition, or a secure, compliant portal to complete the ordering process.
Leave the rest to us.
We will notify you when your patient’s results are ready.
You will have the option to request a consult with a genetic counsellor, whether to review your patient’s results and/or to follow-up with your patient, as needed.
If your question is not shown here, please Contact us directly.
geneType™ for Pancreatic Cancer is a pancreatic cancer risk assessment test for adults aged 30 years or older.
This test is not applicable to adults who have a personal history of pancreatic cancer or who have already been shown to have a cancer mutation, for example in the CDKN2A gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of pancreatic cancer.
Cancer is a multifactorial disease and there are many different risk factors. Of these, geneType™ integrates the most predictive risk factors into the model. Future models may include additional risk factors as the scientific community’s understanding of pancreatic cancer continues to evolve.
No. At this time geneType™ is a self-pay test. However, your patient may use FSA/HSA to pay for the test.
geneType™ is a risk assessment tool to enable you to stratify your patient population.
Liquid biopsies, such as the Galleri test are novel, but pricey screening options.
A risk stratification tool can be used to identify your patients that might benefit from a novel screening tool like this one.
*Patient eligibility dependent on personal medical history, age and sex
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for eight diseases in the panel; a man would be eligible for seven. Starting at age 30, a patient may qualify for geneType’s™ cancer risk assessments only.
Accredited For Compliance With NPAAC Standards And ISO 15189
